Sri Krishna (Krish)
@tellkrish.bsky.social
Stadtman Investigator @ Surgery Branch, NCI | Immunology & Cancer, T Cells & Mutations |
Views don't represent NIH, HHS or US GOV
|🇮🇳🇺🇸| Lab: https://ccr.cancer.gov/staff-directory/sri-krishna
Views don't represent NIH, HHS or US GOV
|🇮🇳🇺🇸| Lab: https://ccr.cancer.gov/staff-directory/sri-krishna
Several interesting correlates show up - most of the responses were in patients who have not received TIL targeting the same mutation, and targeting CD8 neoantigens. They were nevertheless not durable (unlike TIL in melanoma) 2/3
November 24, 2024 at 5:03 PM
Several interesting correlates show up - most of the responses were in patients who have not received TIL targeting the same mutation, and targeting CD8 neoantigens. They were nevertheless not durable (unlike TIL in melanoma) 2/3